有乳腺癌个人史女性乳房MRI补充筛查阴性后间期癌的研究
该研究回顾性分析了2008年1月至2019年3月期间2809例有乳腺癌个人史女性的6603次筛查乳房MRI,评估多轮筛查性能和间期癌风险因素。癌症检出率为每1000次筛查8.3例,间期癌率为每1000次筛查1.5例,敏感度85%、特异度88.3%。间期癌与乳腺癌一级亲属家族史、雌激素受体和孕激素受体阴性原发癌及中度或明显背景实质强化独立相关。
要点
- 有乳腺癌个人史女性筛查MRI的癌症检出率为8.3/1000,间期癌率为1.5/1000。
- MRI筛查敏感度85%、特异度88.3%,多轮筛查性能持续稳定。
- 一级亲属乳腺癌家族史、ER/PR阴性原发癌及中度或明显背景实质强化与间期癌风险独立相关。
核心结论
- 有乳腺癌个人史女性的筛查乳房MRI在多轮筛查中性能持续稳定,乳腺癌一级亲属家族史、雌激素受体和孕激素受体阴性原发癌及MRI上中度或明显背景实质强化与间期癌发生风险独立相关。
诊断标准与关键数值
- 癌症检出率为每1000次筛查检查8.3例(55/6603次检查);间期癌率为每1000次筛查检查1.5例(10/6603次检查);敏感度为85%(55/65次检查;95%CI:76,93);特异度为88.3%(5775/6538次检查;95%CI:87.6,89.1)。
临床应用与阅片要点
- 对有乳腺癌个人史女性进行筛查乳房MRI时,应关注一级亲属乳腺癌家族史、雌激素受体和孕激素受体阴性原发癌及中度或明显背景实质强化等与间期癌风险独立相关的因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background There are few interval cancer studies of incident screening MRI for women with a personal history of breast cancer (PHBC). Purpose To evaluate the performance measures of screening breast MRI in women with a PHBC across multiple rounds and to identify subgroups who might be more at risk for interval cancer. Materials and Methods Between January 2008 and March 2019, consecutive screening breast MRI studies for women who had undergone breast-conserving surgery because of breast cancer were retrospectively identified. Inclusion criteria were negative or benign findings at mammography with US, availability of at least 1 year of follow-up data, and examinations having been performed within 12 months after the initial cancer surgery. Performance measures were calculated for each round. Multivariable logistic regression analysis was performed to determine factors associated with the risk of interval cancer. Results Among the 6603 MRI examinations for 2809 women (median age, 47 years; interquartile range, 42-53 years), the cancer detection rate was 8.3 per 1000 screening examinations (55 of 6603 examinations) and the interval cancer rate was 1.5 per 1000 screening examinations (10 of 6603 examinations). The sensitivity and specificity were 85% (55 of 65 examinations; 95% CI: 76, 93) and 88.3% (5775 of 6538 examinations; 95% CI: 87.6, 89.1), respectively. At multivariable analysis, interval cancers were associated with a first-degree family history of breast cancer (odds ratio [OR], 5.4; 95% CI: 1.3, 22.5; P = .02), estrogen receptor- and progesterone receptor-negative primary cancers (OR, 3.6; 95% CI: 1.1, 12.2; P = .04), and moderate or marked background parenchymal enhancement (OR, 10.8; 95% CI: 3.3, 35.7; P < .001). Conclusion Performance of screening breast MRI in women with a personal history of breast cancer was sustained across multiple rounds, and a first-degree family history of breast cancer, estrogen receptor- and progesterone receptor-negative primary cancers, and moderate or marked background parenchymal enhancement at MRI were independently associated with the risk of developing interval cancers. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Slanetz in this issue.
引用
- Kim GR, Cho N, Kim SY, et al. Interval Cancers after Negative Supplemental Screening Breast MRI Results in Women with a Personal History of Breast Cancer. Radiology. 2021. PMID: 34100684. doi:10.1148/radiol.2021203074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。